摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenyl)ethynyl)quinoline | 1443361-07-6

中文名称
——
中文别名
——
英文名称
2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenyl)ethynyl)quinoline
英文别名
2-[2-[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenyl]ethynyl]quinoline
2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenyl)ethynyl)quinoline化学式
CAS
1443361-07-6
化学式
C26H18N4
mdl
——
分子量
386.456
InChiKey
YQJGCTAJURKZFR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    30
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.04
  • 拓扑面积:
    43.6
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    1-(4-溴苯基)-2-吡啶-4-乙酮 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide四丁基氟化铵三乙胺 作用下, 以 四氢呋喃1,4-二氧六环甲醇 为溶剂, 反应 5.16h, 生成 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenyl)ethynyl)quinoline
    参考文献:
    名称:
    ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF
    摘要:
    这项发明涉及新型炔基桥联的杂环芳烃,如规范中所述,这些化合物是PDE10A抑制剂,可用于治疗神经病、精神障碍、代谢性疾病,如精神分裂症、帕金森病、亨廷顿病、阿尔茨海默病、学习记忆障碍、药物成瘾(滥用)、睡眠障碍、抑郁症、肥胖症、非胰岛素依赖型糖尿病、躁郁症、强迫症或疼痛;以及它们的制备方法;包含它们的药物组合物;以及使用它们的方法。
    公开号:
    US20130158031A1
点击查看最新优质反应信息

文献信息

  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    申请人:ABBVIE INC.
    公开号:US20140148461A1
    公开(公告)日:2014-05-29
    The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. wherein Y 1 and Y 2 are adjacent atoms in Het 1 , which are independently selected from the group consisting of carbon and nitrogen; k is 0, 1, 2 or 3; Het 1 is a bivalent monocyclic 5- or 6-membered heteroaromatic radical, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N—R a as ring members, or a bivalent fused bicyclic 8-, 9- or 10-membered heteroaromatic radical, having 1, 2, 3 or 4 heteroatoms or heteroatom moieties selected from O, S, N and N—R a as ring members; Het 2 is inter alia monocyclic 5- or 6-membered hetaryl, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N—R 1a as ring members, Cyc is inter alia optionally substituted monocyclic 5- or 6-membered hetaryl or optionally substituted fused 8-, 9- or 10-membered bicyclic hetaryl; Ar is optionally substituted phenylene or optionally substituted bivalent 6-membered hetaryl; R is attached to a carbon atom of Het 1 and inter alia-halogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 1 -C 6 -alkoxy, C 1 -C 6 -fluoroalkyl, C 1 -C 6 -fluoroalkoxy, C 3 -C 6 -cycloalkyl etc.
    该发明涉及公式I的化合物及其盐等,这些化合物是磷酸二酯酶10A的抑制剂,用于制造药物,并因此适用于治疗或控制神经疾病和精神疾病等医学疾病,改善与这些疾病相关的症状,并降低这些疾病的风险。 其中Y1和Y2是Het1中相邻的原子,独立地选自由碳和氮组成的群;k为0、1、2或3;Het1是双价的单环5-或6-成员杂芳基,具有1、2或3个杂原子或杂原子基,选自O、S、N和N—Ra作为环成员,或者是双价的融合的8、9或10-成员杂芳基,具有1、2、3或4个杂原子或杂原子基,选自O、S、N和N—Ra作为环成员;Het2是单环5-或6-成员杂芳基,具有1、2或3个杂原子或杂原子基,选自O、S、N和N—R1a作为环成员,Cyc是可选取代的单环5-或6-成员杂芳基或可选取代的融合的8、9或10-成员双环杂芳基;Ar是可选取代的苯基或可选取代的双价6-成员杂芳基;R连接到Het1的碳原子上,包括卤素、C1-C6-烷基、C2-C6-烯基、C2-C6-炔基、C1-C6-烷氧基、C1-C6-氟烷基、C1-C6-氟烷氧基、C3-C6-环烷基等。
  • INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    申请人:AbbVie Inc.
    公开号:EP2922842B1
    公开(公告)日:2017-06-14
  • COMPOSITIONS AND USES THEREOF
    申请人:BenevolentAI Cambridge Limited
    公开号:EP4103161A1
    公开(公告)日:2022-12-21
  • US9790203B2
    申请人:——
    公开号:US9790203B2
    公开(公告)日:2017-10-17
  • [EN] NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS DE PHOSPHODIESTÉRASE DE TYPE 10A
    申请人:ABBVIE INC
    公开号:WO2014079995A2
    公开(公告)日:2014-05-30
    The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders wherein Y1 and Y2 are adjacent atoms in Het1, which are independently selected from the group consisting of carbon and nitrogen; k is 0, 1, 2 or 3; Het1 is a bivalent monocyclic 5- or 6-membered heteroaromatic radical, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N-Ra as ring members, or a bivalent fused bicyclic 8-, 9- or 10-membered heteroaromatic radical, having 1, 2, 3 or 4 heteroatoms or heteroatom moieties selected from O, S, N and N-Ra as ring members; Het2 is inter alia monocyclic 5- or 6-membered hetaryl, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N-R1a as ring members, Cyc is inter alia optionally substituted monocyclic 5- or 6-membered hetaryl or optionally substituted fused 8-, 9- or 10-membered bicyclic hetaryl; Ar is optionally substituted phenylene or optionally substituted bivalent 6-membered hetaryl; R is attached to a carbon atom of Het1 and inter alia - halogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-fluoroalkyl, C1-C6-fluoroalkoxy, C3-C6-cycloalkyl etc.
查看更多